Skip to main content
. 2003 Oct 14;89(8):1439–1444. doi: 10.1038/sj.bjc.6601310

Table 5. Tumoral responses.

  All patients, n=66 (%) First line, n=27 (%) Second line, n=34 (%) Group 1, n=48 (%) Group 2, n=18 (%)
Complete response 1 (1.5) 1 (4) 0 0 1 (6)
Partial response 13 (20) 9 (33) 4 (12) 11 (23) 2 (11)
Stable disease 31 (47) 12 (44) 17 (50) 20 (42) 11 (61)
Progression 18 (27) 4 (15) 12 (35) 14 (29) 4 (22)
Not evaluable 3 (4.5) 1 (4) 1 (3) 3 (6) 0